CoChat

Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-β

Open access

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

Transforming growth factor β (TGF-β) isoforms are secreted as inactive complexes formed through noncovalent interactions between the bioactive TGF-β entity and its N-terminal latency-associated peptide prodomain. Extracellular activation of the latent TGF-β complex is a crucial step in the regulation of TGF-β function for tissue homeostasis. We show that the fibrinogen-like (FBG) domain of the matrix glycoprotein tenascin-X (TNX) interacts physically with the small latent TGF-β complex in vitro and in vivo, thus regulating the bioavailability of mature TGF-β to cells by activating the latent cytokine into an active molecule. Activation by the FBG domain most likely occurs through a conformational change in the latent complex and involves a novel cell adhesion–dependent mechanism. We identify α11β1 integrin as a cell surface receptor for TNX and show that this integrin is crucial to elicit FBG-mediated activation of latent TGF-β and subsequent epithelial-to-mesenchymal transition in mammary epithelial cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1083/jcb.201308031

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Recombinant TNX fragments differentially regulate EMT in mammary epithelial cells. (A) The recombinant TNX fragments (solid lines) are depicted below the schematic diagram representing the full-length TNX monomer. (B) Phase-contrast images of NMuMG cells cultured for 48 h either in the presence of soluble recombinant human TGF-β1 (2 ng/ml) or after seeding onto noncoated dishes or dishes coated (111 pmol/cm2) with recombinant full-length TNX, TNXΔEΔF fragment, or FBG domain. Bars, 30 µm. (C) F-actin direct fluorescence and E-cadherin indirect immunofluorescence were performed in NMuMG cells cultured as described in B. Bars, 15 µm.
Figure 1. Recombinant TNX fragments differentially regulate EMT in mammary epithelial cells. (A) The recombinant TNX fragments (solid lines) are depicted below the schematic diagram representing the full-length TNX monomer. (B) Phase-contrast images of NMuMG cells cultured for 48 h either in the presence of soluble recombinant human TGF-β1 (2 ng/ml) or after seeding onto noncoated dishes or dishes coated (111 pmol/cm2) with recombinant full-length TNX, TNXΔEΔF fragment, or FBG domain. Bars, 30 µm. (C) F-actin direct fluorescence and E-cadherin indirect immunofluorescence were performed in NMuMG cells cultured as described in B. Bars, 15 µm.CC BY-NC-SA · PubMed Central
Figure 2. The FNIII repeats of TNX molecule inhibit the EMT induced by the FBG domain in mammary epithelial cells. (A) Phase-contrast images of NMuMG cells cultured for 48 h either in the presence of soluble recombinant human TGF-β1 (2 ng/ml) or after seeding onto noncoated dishes or dishes coated (111 pmol/cm2) with the TNXΔEΔF fragment, the FBG domain, or both recombinant proteins. Bars, 30 µm. (B) F-actin direct fluorescence and E-cadherin indirect immunofluorescence were performed in NMuMG cells cultured as described in A. Bars, 15 µm.
Figure 2. The FNIII repeats of TNX molecule inhibit the EMT induced by the FBG domain in mammary epithelial cells. (A) Phase-contrast images of NMuMG cells cultured for 48 h either in the presence of soluble recombinant human TGF-β1 (2 ng/ml) or after seeding onto noncoated dishes or dishes coated (111 pmol/cm2) with the TNXΔEΔF fragment, the FBG domain, or both recombinant proteins. Bars, 30 µm. (B) F-actin direct fluorescence and E-cadherin indirect immunofluorescence were performed in NMuMG cells cultured as described in A. Bars, 15 µm.CC BY-NC-SA · PubMed Central
Figure 3. The FBG domain of TNX stimulates the TGF-β–Smad signaling pathway. (A) Phase-contrast microscopy (top) and F-actin direct fluorescence (bottom) applied to NMuMG cells cultured for 36 h on noncoated or 222 pmol/cm2 FBG-coated dishes, or stimulated with 5 ng/ml of soluble TGF-β1, in the presence of 10 µM SB431542 or vehicle (DMSO). Bars, 30 µm. (B) Firefly luciferase activity in MCF10A-TRE-Luc cells cultured for 16 h as described in A. *, P < 0.05 versus control condition. Error bars are means ± SD. (C) Immunoblot analyses showing levels of phosphorylated Smad2 (P-Smad2) and total Smad2/3 in NMuMG cells cultured in noncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes or stimulated with 5 ng/ml of mature TGF-β1 for the indicated time. Ratio of phospho-Smad2 to total Smad2/3 levels is indicated below. (D) Phospho-Smad2 levels in NMuMG cells cultured for 3 h as described in A.
Figure 3. The FBG domain of TNX stimulates the TGF-β–Smad signaling pathway. (A) Phase-contrast microscopy (top) and F-actin direct fluorescence (bottom) applied to NMuMG cells cultured for 36 h on noncoated or 222 pmol/cm2 FBG-coated dishes, or stimulated with 5 ng/ml of soluble TGF-β1, in the presence of 10 µM SB431542 or vehicle (DMSO). Bars, 30 µm. (B) Firefly luciferase activity in MCF10A-TRE-Luc cells cultured for 16 h as described in A. *, P < 0.05 versus control condition. Error bars are means ± SD. (C) Immunoblot analyses showing levels of phosphorylated Smad2 (P-Smad2) and total Smad2/3 in NMuMG cells cultured in noncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes or stimulated with 5 ng/ml of mature TGF-β1 for the indicated time. Ratio of phospho-Smad2 to total Smad2/3 levels is indicated below. (D) Phospho-Smad2 levels in NMuMG cells cultured for 3 h as described in A.CC BY-NC-SA · PubMed Central
Figure 4. The FBG domain of TNX activates latent TGF-β in vitro. (A) Immunoblots showing phospho-Smad2 (P-Smad2) levels in NMuMG cells incubated for 3 h on either noncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes or stimulated for 3 h with 5 ng/ml of soluble human TGF-β1 in the presence of 10 µg/ml cycloheximide or the corresponding vehicle (DMSO). (B) Immunoblots showing levels of phospho-Smad2 in NMuMG cells incubated for 3 h on either noncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes or stimulated for 3 h with 5 ng/ml TGF-β1 in the presence of a control IgG or 10 µg/ml anti-pan–TGF-β antibody. (C) Firefly luciferase activity in MCF10A-TRE-Luc cells cultured for 16 h under the same conditions as described in B. *, P < 0.05 versus control IgG. Error bars are means ± SD. (D) F-actin direct fluorescence (top) and indirect immunofluorescence staining of E-cadherin (bottom) performed in NMuMG cells cultured for 36 h under the same conditions as described in B. Bars, 15 µm.
Figure 4. The FBG domain of TNX activates latent TGF-β in vitro. (A) Immunoblots showing phospho-Smad2 (P-Smad2) levels in NMuMG cells incubated for 3 h on either noncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes or stimulated for 3 h with 5 ng/ml of soluble human TGF-β1 in the presence of 10 µg/ml cycloheximide or the corresponding vehicle (DMSO). (B) Immunoblots showing levels of phospho-Smad2 in NMuMG cells incubated for 3 h on either noncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes or stimulated for 3 h with 5 ng/ml TGF-β1 in the presence of a control IgG or 10 µg/ml anti-pan–TGF-β antibody. (C) Firefly luciferase activity in MCF10A-TRE-Luc cells cultured for 16 h under the same conditions as described in B. *, P < 0.05 versus control IgG. Error bars are means ± SD. (D) F-actin direct fluorescence (top) and indirect immunofluorescence staining of E-cadherin (bottom) performed in NMuMG cells cultured for 36 h under the same conditions as described in B. Bars, 15 µm.CC BY-NC-SA · PubMed Central
Figure 5. The FBG domain of TNX interacts physically with the SLC in vitro and in vivo. (A) Quantitative (ELISA) analysis of mature human TGF-β1 associated with equimolar concentrations (111 nM) of purified recombinant FBG domain, full-length TNX, or TNXΔEΔF fragment, subjected (+) or not subjected (−) to conditions activating latent TGF-β (heat and acid treatments). (B) Levels of mature human TGF-β1 and of its LAP(β1) propeptide associated with equimolar concentrations (111 nM) of purified recombinant FBG domain, full-length TNX, or TNXΔEΔF protein were determined by immunoblotting. The monoclonal anti-TNX antibody recognizes the 10th FNIII domain. (C) Levels of phospho-Smad2 (P-Smad2) in NMuMG cells cultured for 3 h on noncoated dishes (N-C) or dishes coated with the different recombinant TNX variants (111 pmol/cm2) or stimulated with 5 ng/ml of soluble TGF-β1. Ratio of phospho-Smad2 to total Smad2/3 levels is indicated below. (D) Coimmunoprecipitation of the mature TGF-β1 entity and of its LAP(β1) propeptide with the purified recombinant FBG domain. Immunoprecipitations were performed with anti-FBG (α-FBG), anti-–human TGF-β1 (α-TGF-β1), or anti–human LAP(β1) antibodies or with control IgG. (E) Quantitative detection (ELISA) of mature TGF-β1 associated with the FBG domain of bovine TNX immunoprecipitated from FBS with either anti-FBG domain (α-FBG) antibody or control IgG. Samples were subjected (+) or not subjected (−) to activating conditions before the ELISA. An FBS fraction corresponding to 2.5% of the total volume used for the immunoprecipitation was also subjected to ELISA. *, P < 0.05. Error bars are means ± SD. IP, immunoprecipitation.
Figure 5. The FBG domain of TNX interacts physically with the SLC in vitro and in vivo. (A) Quantitative (ELISA) analysis of mature human TGF-β1 associated with equimolar concentrations (111 nM) of purified recombinant FBG domain, full-length TNX, or TNXΔEΔF fragment, subjected (+) or not subjected (−) to conditions activating latent TGF-β (heat and acid treatments). (B) Levels of mature human TGF-β1 and of its LAP(β1) propeptide associated with equimolar concentrations (111 nM) of purified recombinant FBG domain, full-length TNX, or TNXΔEΔF protein were determined by immunoblotting. The monoclonal anti-TNX antibody recognizes the 10th FNIII domain. (C) Levels of phospho-Smad2 (P-Smad2) in NMuMG cells cultured for 3 h on noncoated dishes (N-C) or dishes coated with the different recombinant TNX variants (111 pmol/cm2) or stimulated with 5 ng/ml of soluble TGF-β1. Ratio of phospho-Smad2 to total Smad2/3 levels is indicated below. (D) Coimmunoprecipitation of the mature TGF-β1 entity and of its LAP(β1) propeptide with the purified recombinant FBG domain. Immunoprecipitations were performed with anti-FBG (α-FBG), anti-–human TGF-β1 (α-TGF-β1), or anti–human LAP(β1) antibodies or with control IgG. (E) Quantitative detection (ELISA) of mature TGF-β1 associated with the FBG domain of bovine TNX immunoprecipitated from FBS with either anti-FBG domain (α-FBG) antibody or control IgG. Samples were subjected (+) or not subjected (−) to activating conditions before the ELISA. An FBS fraction corresponding to 2.5% of the total volume used for the immunoprecipitation was also subjected to ELISA. *, P < 0.05. Error bars are means ± SD. IP, immunoprecipitation.CC BY-NC-SA · PubMed Central
Figure 6. The FBG domain of TNX devoid of TGF-β activity retains the ability to activate cell-secreted latent TGF-β1. (A) The FBG domain was stripped of TGF-β1–associated activity under alkaline conditions. (top) ELISA quantitation of total active human TGF-β1 was performed with 2.5 µg protein from untreated FBG domain (input fraction) or from unbound and bound fractions of purified FBG domain under alkaline conditions. (bottom) Immunoblot analyses of TGF-β1 and the FBG domain were performed in parallel on the same fractions (2.5 µg protein). (B) Western blot analysis of phospho-Smad2 (P-Smad2) in NMuMG cells cultured for 3 h with the different fractions (50 µg/ml) containing the FBG domain stripped of TGF-β1–associated activity (bound fraction) or unbound (flow through) and wash fractions as described in A. As a control, untreated or alkaline-treated BSA was used instead of FBG domain. Ratio of phospho-Smad2 to actin levels is indicated below. (C) Firefly luciferase activity in NMuMG cells transiently transfected with the Smad-responsive (CAGA)9-Luc reporter construct. The cells were incubated for 24 h with either recombinant TGF-β1 (5 ng/ml) or the different fractions (50 µg/ml) containing the FBG domain subjected or not subjected to alkaline treatment described in A. N-C, noncoated. (D, top) SDS-PAGE analysis of purified FBG domain produced in mammalian cells (FBG) and in E. coli (FBG*). MM, molecular mass markers. (bottom) Immunoblot analysis of the levels of mature human TGF-β1 and of its LAP(β1) propeptide associated with purified FBG domain (111 nM each). (E) Immunoblot analysis of phospho-Smad2 in NMuMG cells cultured for 3 h with 5 ng/ml TGF-β1, soluble purified FBG domain (111 nM) produced in mammalian cells (FBG) or in E. coli (FBG*), or the corresponding vehicle (PBS). Ratio of phospho-Smad2 to total Smad2/3 levels is indicated below. (F) Firefly luciferase activity of MCF10A-TRE-Luc cells incubated for 24 h as described in E. (G) F-actin direct fluorescence (top) and indirect immunofluorescence staining of E-cadherin (bottom) performed in NMuMG cells cultured for 48 h with soluble FBG domains produced in eukaryotic (FBG) or prokaryotic (FBG*) system (111 nM). Bars, 15 µm. *, P < 0.05 versus control condition. Error bars are means ± SD. WB, Western blot.
Figure 6. The FBG domain of TNX devoid of TGF-β activity retains the ability to activate cell-secreted latent TGF-β1. (A) The FBG domain was stripped of TGF-β1–associated activity under alkaline conditions. (top) ELISA quantitation of total active human TGF-β1 was performed with 2.5 µg protein from untreated FBG domain (input fraction) or from unbound and bound fractions of purified FBG domain under alkaline conditions. (bottom) Immunoblot analyses of TGF-β1 and the FBG domain were performed in parallel on the same fractions (2.5 µg protein). (B) Western blot analysis of phospho-Smad2 (P-Smad2) in NMuMG cells cultured for 3 h with the different fractions (50 µg/ml) containing the FBG domain stripped of TGF-β1–associated activity (bound fraction) or unbound (flow through) and wash fractions as described in A. As a control, untreated or alkaline-treated BSA was used instead of FBG domain. Ratio of phospho-Smad2 to actin levels is indicated below. (C) Firefly luciferase activity in NMuMG cells transiently transfected with the Smad-responsive (CAGA)9-Luc reporter construct. The cells were incubated for 24 h with either recombinant TGF-β1 (5 ng/ml) or the different fractions (50 µg/ml) containing the FBG domain subjected or not subjected to alkaline treatment described in A. N-C, noncoated. (D, top) SDS-PAGE analysis of purified FBG domain produced in mammalian cells (FBG) and in E. coli (FBG*). MM, molecular mass markers. (bottom) Immunoblot analysis of the levels of mature human TGF-β1 and of its LAP(β1) propeptide associated with purified FBG domain (111 nM each). (E) Immunoblot analysis of phospho-Smad2 in NMuMG cells cultured for 3 h with 5 ng/ml TGF-β1, soluble purified FBG domain (111 nM) produced in mammalian cells (FBG) or in E. coli (FBG*), or the corresponding vehicle (PBS). Ratio of phospho-Smad2 to total Smad2/3 levels is indicated below. (F) Firefly luciferase activity of MCF10A-TRE-Luc cells incubated for 24 h as described in E. (G) F-actin direct fluorescence (top) and indirect immunofluorescence staining of E-cadherin (bottom) performed in NMuMG cells cultured for 48 h with soluble FBG domains produced in eukaryotic (FBG) or prokaryotic (FBG*) system (111 nM). Bars, 15 µm. *, P < 0.05 versus control condition. Error bars are means ± SD. WB, Western blot.CC BY-NC-SA · PubMed Central
Figure 7. Mature TGF-β activated by the FBG domain of TNX is not diffusible, and its activation does not require any proteolytic event. (A) Phosphorylated Smad2 (P-Smad2) level in NMuMG cells seeded onto 222 pmol/cm2 FBG-coated (+) or uncoated (−) dishes and cultured for 3 h in the absence (vehicle) or presence of the indicated protease inhibitor (10 µM) or recombinant TGF-β1 (5 ng/ml). #, nonspecific band. (B) Culture of recipient MCF10A-TRE-Luc reporter cells with conditioned medium (CM) from donor NMuMG cells seeded onto a noncoated (N-C) or a 222 pmol/cm2 FBG-coated dish or treated with 5 ng/ml of mature TGF-β1 for 1–6 h. (C) Firefly luciferase activity of MCF10A-TRE-Luc cells cultured for 24 h with NMuMG cell–conditioned medium (top) and phospho-Smad2 levels in the donor NMuMG cells (bottom). White lines indicate that intervening lanes have been spliced out. (D) Co-culture assay of recipient MCF10A-TRE-Luc reporter cells (bottom well) with donor NMuMG cells (top well) seeded onto a porous membrane (pore size of 0.4 µm) coated or not coated with 222 pmol/cm2 of recombinant FBG domain or treated with 5 ng/ml of mature TGF-β1. (E) Firefly luciferase activity of MCF10A-TRE-Luc cells co-cultured for 24 h with or without NMuMG cells in the presence or absence of FBG domain or TGF-β1 as described in D. *, P < 0.05 versus uncoated condition. Error bars are means ± SD.
Figure 7. Mature TGF-β activated by the FBG domain of TNX is not diffusible, and its activation does not require any proteolytic event. (A) Phosphorylated Smad2 (P-Smad2) level in NMuMG cells seeded onto 222 pmol/cm2 FBG-coated (+) or uncoated (−) dishes and cultured for 3 h in the absence (vehicle) or presence of the indicated protease inhibitor (10 µM) or recombinant TGF-β1 (5 ng/ml). #, nonspecific band. (B) Culture of recipient MCF10A-TRE-Luc reporter cells with conditioned medium (CM) from donor NMuMG cells seeded onto a noncoated (N-C) or a 222 pmol/cm2 FBG-coated dish or treated with 5 ng/ml of mature TGF-β1 for 1–6 h. (C) Firefly luciferase activity of MCF10A-TRE-Luc cells cultured for 24 h with NMuMG cell–conditioned medium (top) and phospho-Smad2 levels in the donor NMuMG cells (bottom). White lines indicate that intervening lanes have been spliced out. (D) Co-culture assay of recipient MCF10A-TRE-Luc reporter cells (bottom well) with donor NMuMG cells (top well) seeded onto a porous membrane (pore size of 0.4 µm) coated or not coated with 222 pmol/cm2 of recombinant FBG domain or treated with 5 ng/ml of mature TGF-β1. (E) Firefly luciferase activity of MCF10A-TRE-Luc cells co-cultured for 24 h with or without NMuMG cells in the presence or absence of FBG domain or TGF-β1 as described in D. *, P < 0.05 versus uncoated condition. Error bars are means ± SD.CC BY-NC-SA · PubMed Central
Figure 8. TSP-1 is not required for FBG-mediated activation of latent TGF-β. (A) Immunoblots showing phospho-Smad2 (P-Smad2) levels in NMuMG cells cultured for 3 h with (+) or without (−) soluble purified TSP-1 (11 nM) in the presence of neutralizing anti–TSP-1 antibody (α-TSP1) or normal serum IgG (10 µg/ml). (B) Levels of phosphorylated Smad2 in NMuMG cells cultured for 3 h on noncoated (N-C) or 222 pmol/cm2 FBG-coated dishes or treated with 5 ng/ml of mature TGF-β1 in the presence of neutralizing anti–TSP-1 antibody as described in A. (C) Levels of phospho-Smad2 in NMuMG cells cultured for 3 h with (+) or without (−) 11 nM of soluble purified TSP-1 in the presence of a competing (LSKL) or control (SLLK) peptide (10 µM). (D) Phospho-Smad2 levels in NMuMG cells cultured for 3 h on noncoated (−) or FBG-coated (+) dishes, in the absence (−) or presence of competing or control peptide as described in C.
Figure 8. TSP-1 is not required for FBG-mediated activation of latent TGF-β. (A) Immunoblots showing phospho-Smad2 (P-Smad2) levels in NMuMG cells cultured for 3 h with (+) or without (−) soluble purified TSP-1 (11 nM) in the presence of neutralizing anti–TSP-1 antibody (α-TSP1) or normal serum IgG (10 µg/ml). (B) Levels of phosphorylated Smad2 in NMuMG cells cultured for 3 h on noncoated (N-C) or 222 pmol/cm2 FBG-coated dishes or treated with 5 ng/ml of mature TGF-β1 in the presence of neutralizing anti–TSP-1 antibody as described in A. (C) Levels of phospho-Smad2 in NMuMG cells cultured for 3 h with (+) or without (−) 11 nM of soluble purified TSP-1 in the presence of a competing (LSKL) or control (SLLK) peptide (10 µM). (D) Phospho-Smad2 levels in NMuMG cells cultured for 3 h on noncoated (−) or FBG-coated (+) dishes, in the absence (−) or presence of competing or control peptide as described in C.CC BY-NC-SA · PubMed Central
Figure 9. Activation of latent TGF-β by the FBG domain requires cell adhesion and the α11β1 integrin. (A) Adhesion of NMuMG and BL41-(CAGA)9-Luc cells to an increasing quantity of recombinant FBG domain. (B) Luciferase activity of BL41-(CAGA)9-Luc reporter cells cultured for 24 h on coated FBG domain or treated with 5 ng/ml TGF-β1. (C) Adhesion analysis of HT-1080 fibrosarcoma cells transiently expressing a scrambled shRNA or one of two shRNAs (#1 and #2) targeting different sequences of the ITGA11 mRNA and cultured for 30 min onto coated recombinant FBG domain or other TNX fragments (111 pmol/cm2). Results represent the percentage of cell adhesion relative to the scramble shRNA condition for each recombinant protein analyzed. (D) Solid-phase assay of the interaction between the inserted domain of α11 integrin chain in fusion with GST (1 µM) and 5 µg/ml of native or denatured (Denat.) type I collagen or the different TNX derivatives (111 nM). FL, full length. (E) Immunoblotting analysis of phospho-Smad2 and the α11 integrin chain in HT-1080 cells transiently transfected as in C and seeded for 3 h onto uncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes. (F) Firefly luciferase activity of HT-1080 cells transiently cotransfected with the Smad-responsive (CAGA)9-Luc reporter construct and a scrambled or an ITGA11-targeting shRNA and cultured for 24 h in noncoated (N-C) or 222 pmol/cm2 FBG-coated wells. *, P < 0.05 versus control condition. Error bars are means ± SD.
Figure 9. Activation of latent TGF-β by the FBG domain requires cell adhesion and the α11β1 integrin. (A) Adhesion of NMuMG and BL41-(CAGA)9-Luc cells to an increasing quantity of recombinant FBG domain. (B) Luciferase activity of BL41-(CAGA)9-Luc reporter cells cultured for 24 h on coated FBG domain or treated with 5 ng/ml TGF-β1. (C) Adhesion analysis of HT-1080 fibrosarcoma cells transiently expressing a scrambled shRNA or one of two shRNAs (#1 and #2) targeting different sequences of the ITGA11 mRNA and cultured for 30 min onto coated recombinant FBG domain or other TNX fragments (111 pmol/cm2). Results represent the percentage of cell adhesion relative to the scramble shRNA condition for each recombinant protein analyzed. (D) Solid-phase assay of the interaction between the inserted domain of α11 integrin chain in fusion with GST (1 µM) and 5 µg/ml of native or denatured (Denat.) type I collagen or the different TNX derivatives (111 nM). FL, full length. (E) Immunoblotting analysis of phospho-Smad2 and the α11 integrin chain in HT-1080 cells transiently transfected as in C and seeded for 3 h onto uncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes. (F) Firefly luciferase activity of HT-1080 cells transiently cotransfected with the Smad-responsive (CAGA)9-Luc reporter construct and a scrambled or an ITGA11-targeting shRNA and cultured for 24 h in noncoated (N-C) or 222 pmol/cm2 FBG-coated wells. *, P < 0.05 versus control condition. Error bars are means ± SD.CC BY-NC-SA · PubMed Central
Figure 10. α11β1 integrin is required for the induction of EMT by the FBG domain of TNX. (A) Immunoblot analysis of phospho-Smad2 (P-Smad2), total Smad2/3, and the α11 integrin chain in HT-1080 cells transiently expressing, or not expressing (MOCK), α11 integrin subunit and seeded for 3 h onto uncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes. (B) Luciferase activity of BL41-(CAGA)9-Luc reporter cells transiently cotransfected or not transfected (MOCK) with plasmids encoding α11 or β1 integrin chain and cultured for 24 h on coated FBG domain (222 pmol/cm2) or treated with 2 ng/ml TGF-β. Significant (*, P < 0.05) or nonsignificant (ns) difference versus the mock counterpart is indicated for each condition. Error bars are means + SD. N-C, not coated. (C) Direct fluorescence actin staining in MCF10A cells transiently transfected with a scrambled or an ITGA11-targeting shRNA and incubated for 48 h on either a noncoated or 222 pmol/cm2 FBG-coated coverslips. Bars, 10 µm. (D) Model of TGF-β activation by the FBG domain of TNX.
Figure 10. α11β1 integrin is required for the induction of EMT by the FBG domain of TNX. (A) Immunoblot analysis of phospho-Smad2 (P-Smad2), total Smad2/3, and the α11 integrin chain in HT-1080 cells transiently expressing, or not expressing (MOCK), α11 integrin subunit and seeded for 3 h onto uncoated (−) or 222 pmol/cm2 FBG-coated (+) dishes. (B) Luciferase activity of BL41-(CAGA)9-Luc reporter cells transiently cotransfected or not transfected (MOCK) with plasmids encoding α11 or β1 integrin chain and cultured for 24 h on coated FBG domain (222 pmol/cm2) or treated with 2 ng/ml TGF-β. Significant (*, P < 0.05) or nonsignificant (ns) difference versus the mock counterpart is indicated for each condition. Error bars are means + SD. N-C, not coated. (C) Direct fluorescence actin staining in MCF10A cells transiently transfected with a scrambled or an ITGA11-targeting shRNA and incubated for 48 h on either a noncoated or 222 pmol/cm2 FBG-coated coverslips. Bars, 10 µm. (D) Model of TGF-β activation by the FBG domain of TNX.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 94

Metadata

Authors
Alcaraz, L. B., Exposito, J.-Y., Chuvin, N., Pommier, R. M., Cluzel, C., Martel, S., Sentis, S., Bartholin, L., Lethias, C., & Valcourt, U.
Affiliations
Lyon 1 Université (FR)
Corresponding author
Valcourt, Ulrich
Venue
Journal of Cell Biology
Published
2014-05-12
Volume
205
Issue
3
Pages
409-428
ISSN
  • 0021-9525 (ISSN-L)
  • 1540-8140
OpenAlex
W2041801047
Cited by
94
References
66
Citations by year
2026: 4 · 2025: 5 · 2024: 10 · 2023: 12 · 2022: 3 · 2021: 11 · 2020: 10 · 2019: 3 · 2018: 5 · 2017: 8 · 2016: 8 · 2015: 7 · 2014: 8
FWCI
4.23
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Cell Biology (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords
tenascin-X, epithelial-mesenchymal transition, latent TGF-beta activation, fibrinogen-like domain, cell adhesion, mammary epithelial cells, extracellular matrix, conformational change
MeSH terms
Animals, Cattle, Cell Adhesion, Epithelial Cells, Female, Humans, Mammary Glands, Animal, Phosphorylation, Protein Binding, Protein Conformation, Protein Precursors, Recombinant Proteins, Transfection, Signal Transduction, Integrins, Tenascin, RNA Interference, Receptors, Collagen, Mammary Glands, Human, Cell Line, Tumor, Mice, Smad Proteins, Transforming Growth Factor beta1, Protein Interaction Domains and Motifs, HEK293 Cells, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.